Mutual of America Capital Management LLC boosted its stake in shares of Becton, Dickinson and Company (NYSE:BDX) by 2.6% in the second quarter, according to its most recent disclosure with the SEC. The firm owned 40,751 shares of the medical instruments supplier’s stock after acquiring an additional 1,050 shares during the period. Mutual of America Capital Management LLC’s holdings in Becton, Dickinson and were worth $7,951,000 at the end of the most recent quarter.

A number of other large investors also recently bought and sold shares of the business. New York State Common Retirement Fund raised its position in Becton, Dickinson and by 25.3% during the second quarter. New York State Common Retirement Fund now owns 936,270 shares of the medical instruments supplier’s stock worth $182,676,000 after acquiring an additional 189,183 shares during the period. BRYN MAWR TRUST Co raised its position in Becton, Dickinson and by 0.4% during the second quarter. BRYN MAWR TRUST Co now owns 152,696 shares of the medical instruments supplier’s stock worth $29,793,000 after acquiring an additional 584 shares during the period. Acrospire Investment Management LLC raised its position in Becton, Dickinson and by 259.7% during the second quarter. Acrospire Investment Management LLC now owns 831 shares of the medical instruments supplier’s stock worth $162,000 after acquiring an additional 600 shares during the period. Investec Asset Management LTD raised its position in Becton, Dickinson and by 14.5% during the second quarter. Investec Asset Management LTD now owns 455,628 shares of the medical instruments supplier’s stock worth $88,898,000 after acquiring an additional 57,736 shares during the period. Finally, Harvest Fund Management Co. Ltd raised its position in Becton, Dickinson and by 82.8% during the second quarter. Harvest Fund Management Co. Ltd now owns 746 shares of the medical instruments supplier’s stock worth $146,000 after acquiring an additional 338 shares during the period. Institutional investors own 87.12% of the company’s stock.

Shares of Becton, Dickinson and Company (NYSE BDX) opened at 201.43 on Friday. Becton, Dickinson and Company has a one year low of $161.29 and a one year high of $206.63. The company has a 50 day moving average of $197.13 and a 200-day moving average of $193.07. The stock has a market cap of $45.84 billion, a price-to-earnings ratio of 58.33 and a beta of 1.05.

Becton, Dickinson and (NYSE:BDX) last announced its earnings results on Thursday, August 3rd. The medical instruments supplier reported $2.46 earnings per share for the quarter, beating the consensus estimate of $2.44 by $0.02. Becton, Dickinson and had a net margin of 6.25% and a return on equity of 22.53%. The firm had revenue of $3.04 billion during the quarter, compared to the consensus estimate of $3.06 billion. During the same quarter in the previous year, the company posted $2.35 EPS. The firm’s revenue for the quarter was down 5.1% on a year-over-year basis. On average, analysts anticipate that Becton, Dickinson and Company will post $9.46 earnings per share for the current year.

The company also recently announced a quarterly dividend, which was paid on Friday, September 29th. Investors of record on Friday, September 8th were paid a $0.73 dividend. This represents a $2.92 annualized dividend and a yield of 1.45%. The ex-dividend date of this dividend was Thursday, September 7th. Becton, Dickinson and’s payout ratio is 83.43%.

A number of equities analysts have weighed in on BDX shares. Raymond James Financial, Inc. upgraded shares of Becton, Dickinson and from an “outperform” rating to a “strong-buy” rating and reduced their price objective for the stock from $210.00 to $180.00 in a research report on Friday, June 30th. Piper Jaffray Companies restated a “buy” rating and set a $213.00 price objective on shares of Becton, Dickinson and in a research report on Tuesday, September 12th. Bank of America Corporation restated a “buy” rating and set a $225.00 price objective (up from $200.00) on shares of Becton, Dickinson and in a research report on Friday, July 21st. Zacks Investment Research upgraded shares of Becton, Dickinson and from a “hold” rating to a “buy” rating and set a $225.00 target price for the company in a research report on Monday, July 17th. Finally, Wells Fargo & Company assumed coverage on shares of Becton, Dickinson and in a research report on Friday, September 22nd. They issued an “outperform” rating and a $225.00 target price for the company. One equities research analyst has rated the stock with a sell rating, four have given a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the company. Becton, Dickinson and presently has a consensus rating of “Buy” and an average target price of $200.93.

ILLEGAL ACTIVITY NOTICE: This report was first posted by Watch List News and is the property of of Watch List News. If you are accessing this report on another publication, it was stolen and reposted in violation of U.S. & international copyright laws. The correct version of this report can be read at https://www.watchlistnews.com/becton-dickinson-and-company-bdx-shares-bought-by-mutual-of-america-capital-management-llc/1632011.html.

In related news, EVP Ribo Alberto Mas sold 7,463 shares of the business’s stock in a transaction dated Monday, August 14th. The shares were sold at an average price of $201.41, for a total value of $1,503,122.83. Following the completion of the transaction, the executive vice president now owns 29,323 shares of the company’s stock, valued at approximately $5,905,945.43. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Thomas E. Polen, Jr. sold 5,971 shares of the business’s stock in a transaction dated Wednesday, August 9th. The shares were sold at an average price of $197.41, for a total transaction of $1,178,735.11. Following the completion of the transaction, the insider now directly owns 12,861 shares of the company’s stock, valued at approximately $2,538,890.01. The disclosure for this sale can be found here. Insiders sold a total of 75,904 shares of company stock valued at $15,242,688 in the last three months. 1.40% of the stock is currently owned by corporate insiders.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX).

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with Analyst Ratings Network's FREE daily email newsletter.